

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 July 2008 (24.07.2008)

PCT

(10) International Publication Number  
**WO 2008/087529 A1**

(51) International Patent Classification:

*C07D 231/40* (2006.01) *C07D 409/04* (2006.01)  
*C07D 401/04* (2006.01) *C07D 413/12* (2006.01)  
*C07D 403/04* (2006.01) *C07D 473/04* (2006.01)  
*C07D 403/12* (2006.01) *C07D 487/04* (2006.01)  
*C07D 403/14* (2006.01) *A61K 31/4155* (2006.01)  
*C07D 407/04* (2006.01) *A61P 25/00* (2006.01)  
*C07D 407/14* (2006.01)

CN8000-R2108, Princeton, NJ 08543-8000 (US). **VAR-RONE, Maurizio** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **PRATELLI, Carmela** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **HARRISON, Boyd** [US/US]; C/O Wyeth Pharmaceuticals, CN8000-R2108, Princeton, NJ 08543-8000 (US).

(74) Agents: **BANFI, Paolo** et al.; Bianchetti Bracco Minoja S.r.l., Via Plinio, 63, I-20129 Milano (IT).

(21) International Application Number:

PCT/IB2008/000090

(22) International Filing Date: 16 January 2008 (16.01.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/880,629 16 January 2007 (16.01.2007) US

(71) Applicants (for all designated States except US): **SIENA BIOTECH S.P.A.** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **WYETH PHARMACEUTICALS** [US/US]; CN8000-R2108, Princeton, NJ 08543-8000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GHIRON, Chiara** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **NENCINI, Arianna** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **MICCO, Iolanda** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **ZANALETTI, Riccardo** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **MACCARI, Laura** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **BOTHMANN, Hendrick** [DE/IT]; Via Fiorentina, 1, I-53100 Siena (IT). **HAYDAR, Simon** [LB/US]; C/O Wyeth Pharmaceuticals,


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS



(57) Abstract: The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

WO 2008/087529 A1